Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy

Pediatric Nephrology

Volumn 30, Issue 1, 2015, Pages 167-172

  Coppo, Rosanna ^a   Peruzzi, Licia ^a   Amore, Alessandro ^a   Martino, Silvana ^b   Vergano, Luca ^a   Lastauka, Inna ^c   Schieppati, Arrigo ^d   Noris, Marina ^d   Tovo, Pier Angelo ^b   Remuzzi, Giuseppe ^d  

^a CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c BELARUSIAN MEDICAL ACADEMY OF POSTGRADUATE EDUCATION   (Belarus)

^d PAPA GIOVANNI XXIII HOSPITAL   (Italy)

Author keywords

Atypical hemolytic uremic syndrome; C5 inhibition; Eculizumab; Lupus nephritis; Systemic lupus erythematosus; Treatment; Treatment resistant SLE

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ECULIZUMAB; HAPTOGLOBIN; MEROPENEM; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS; MONOCLONAL ANTIBODY;

ABSENCE OF SIDE EFFECTS; ANEMIA; ANTIBIOTIC THERAPY; ARTICLE; CASE REPORT; CHILD; COMPLEMENT BLOOD LEVEL; CORTICOSTEROID THERAPY; DRUG PULSE THERAPY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FEVER; FOLLOW UP; HEMATURIA; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN TISSUE; HYPOTENSION; KIDNEY BIOPSY; KIDNEY FUNCTION; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; MICROANGIOPATHY; OLIGURIA; PLASMAPHERESIS; PLEURA EFFUSION; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; PURPURIC RASH; RASH; RELAPSE; REMISSION; SIDE EFFECT; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TREATMENT DURATION; VASCULITIS; WALKING DIFFICULTY; LUPUS NEPHRITIS; PATHOLOGY; PATHOPHYSIOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD, PRESCHOOL; FEMALE; HUMANS; LUPUS NEPHRITIS;

EID: 84920942686     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-014-2944-y     Document Type: Article

References (15)

1. Maciej L, Hans-Joachim A (2013) The Pathogenesis of Lupus Nephritis. J Am Soc Nephrol 24:1357–1366
2. Elkon KB, Santer DM (2012) Complement, interferon and lupus. Curr Opin Immunol 24:665–670
3. Belot A, Cimaz R (2012) Monogenic forms of systemic lupus erythematosus: new insights into SLE pathogenesis. Pediatr Rheumatol Online J 10:21
4. KDIGO (2012) KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int 2(Suppl 2):139–224
5. Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, Boletis J, Cervera R, Dörner T, Doria A, Ferrario F, Floege J, Houssiau FA, Ioannidis JP, Isenberg DA, Kallenberg CG, Lightstone L, Marks SD, Martini A, Moroni G, Neumann I, Praga M, Schneider M, Starra A, Tesar V, Vasconcelos C, van Vollenhoven RF, Zakharova H, Haubitz M, Gordon C, Jayne D, Boumpas DT, European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (2012) Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 71:1771–1782
6. Braun-Moscovici Y, Butbul-Aviel Y, Guralnik L, Toledano K, Markovits D, Rozin A, Nahir MA, Balbir-Gurman A (2013) Rituximab: rescue therapy in life-threatening complications or refractory autoimmune diseases: a single center experience. Rheumatol Int 33:1495–1504
7. Barilla-Labarca ML, Toder K, Furie R (2013) Targeting the complement system in systemic lupus erythematosus and other diseases. Clin Immunol 148:313–321
8. Wang Y, Hu Q, Madri JA, Rollins SA, Chodera A, Matis LA (1996) Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci U S A 93:8563–8568
9. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277
10. Noris M, Remuzzi G (2009) Atypical hemolytic-uremic syndrome. N Engl J Med 361:1676–1687
11. Sekine H, Kinser TT, Qiao F, Martinez E, Paulling E, Ruiz P, Gilkeson GS, Tomlinson S (2011) The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice. Arthritis Rheum 63:1076–1085
12. Yu F, Tan Y, Zhao MH (2010) Lupus nephritis combined with renal injury due to thrombotic thrombocytopaenic purpura-haemolytic uraemic syndrome. Nephrol Dial Transplant 25:145–152
13. Tschumi S, Gugger M, Bucher BS, Riedl M, Simonetti GD (2011) Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings. Pediatr Nephrol 26:2085–2088
14. Brodsky RA (2009) How I treat paroxysmal nocturnal hemoglobinuria. Blood 113:6522–6527
15. Ariceta G, Arrizabalaga B, Aguirre M, Morteruel E, Lopez-Trascasa M (2012) Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants. Am J Kidney Dis 59:707–710